Regeneron Pharma Is Maintained at Neutral by Cantor Fitzgerald

Regeneron Pharma Is Maintained at Neutral by Cantor

Dow JonesJul 22 11:42 ET

Cantor Fitzgerald Adjusts Price Target on Regeneron Pharmaceuticals to $1,000 From $925

Regeneron Pharmaceuticals (REGN) has an average outperform rating and price target range of $720 to $1,300, according to analysts polled by Capital IQ.Price: 1,069.52, Change: +5.92, Percent Change: +

MT NewswiresJul 22 09:25 ET · Ratings

Express News | Regeneron Pharmaceuticals Inc : Jefferies Raises Target Price to $1,235 From $1,135

ReutersJul 22 07:08 ET

Peering Into Regeneron Pharmaceuticals's Recent Short Interest

Regeneron Pharmaceuticals's (NYSE:REGN) short percent of float has risen 10.17% since its last report. The company recently reported that it has 2.04 million shares sold short, which is 1.95% of all

BenzingaJul 19 12:00 ET

BMO Capital Adjusts Price Target on Regeneron Pharmaceuticals to $1,300 From $1,082, Outperform Rating Maintained

Regeneron Pharmaceuticals (REGN) has an average outperform rating and a price target range of $720 to $1,250, according to analysts polled by Capital IQ.

MT NewswiresJul 19 09:14 ET

Piper Sandler Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Raises Target Price to $1,166

Piper Sandler analyst Christopher Raymond maintains $Regeneron Pharmaceuticals(REGN.US)$ with a buy rating, and adjusts the target price from $1,000 to $1,166.According to TipRanks data, the analyst

Moomoo NewsJul 19 07:34 ET · Ratings